Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2010-12-15 M&A Activity
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
425 Filing
M&A Activity Classification · 95% confidence The document is a press release filed by Novartis AG pursuant to Rule 425 under the Securities Act of 1933, announcing a definitive agreement to merge with Alcon, Inc. It details the terms of the merger, financial impact, strategic rationale, and next steps including shareholder approval and regulatory clearance. The content focuses on merger announcement and related financing and strategic information. It is not a full annual or interim report, audit report, earnings release, or other financial statement. It is not a proxy solicitation or voting results announcement. The document is a merger announcement and related transaction update, fitting the category of M&A Activity (TAR). The length and detail confirm it is the announcement itself, not a brief report publication or regulatory filing. Therefore, the appropriate classification is TAR with high confidence.
2010-12-15 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. It contains detailed information about interim clinical trial results (AZURE trial) for the drug Zometa, including study design, endpoints, and safety information. The document is an investor relations release providing updates on clinical trial outcomes and regulatory plans. It is not a full annual or quarterly financial report, nor is it an audit report, earnings release, or management discussion. It is a regulatory announcement providing material information to investors about clinical trial results and their impact on marketing applications. Given the nature of the document as a regulatory announcement and investor relations release without comprehensive financial statements or management analysis, the best fitting category is Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is not a brief announcement or a full financial report but a detailed regulatory communication.
2010-12-13 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations release announcing clinical trial results for a drug (everolimus) in metastatic breast cancer. It includes detailed study results, safety information, and background on the drug and disease. There are no financial statements, comprehensive financial data, or management discussion of financial results. The document is not an annual or interim report, audit report, earnings release, or any other financial filing. It is a regulatory filing providing material information to investors about clinical trial outcomes and drug development progress. Given the nature and format, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2010-12-13 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations release detailing clinical trial results for a drug (LBH589) in Hodgkin lymphoma patients, including study details, safety, and efficacy data. It is not a full annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information to investors about clinical trial progress and plans for regulatory filings. The document is lengthy (15,000 characters) and contains substantive information but is not a financial report or earnings announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2010-12-07 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. The content is an investor relations release announcing 24-month Phase III clinical trial data for the drug Tasigna compared to Glivec in treating chronic myeloid leukemia. It includes detailed clinical trial results, regulatory approval status, and safety information. The document is not a full annual or quarterly financial report, nor is it a transcript, audit, or governance document. It is a regulatory filing providing material information to investors about clinical trial outcomes and drug approvals. The length is about 15,000 characters, indicating a substantive report rather than a brief announcement. Since Form 6-K filings are generally classified as Regulatory Filings (RNS) unless they contain full financial statements or detailed financial analysis, and this document primarily contains clinical trial and regulatory update information without financial statements, the appropriate classification is Regulatory Filings (RNS).
2010-12-06 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer submitted to the SEC. The content is an investor relations press release announcing clinical trial results for the drug Zometa, including survival benefits in multiple myeloma patients. It is not a full financial report, audit, or earnings release. It is a regulatory announcement providing material information to investors but does not contain comprehensive financial statements or detailed management discussion. The document length is about 15,000 characters, but the content is primarily a press release with clinical data and safety information, typical of a regulatory filing under Form 6-K. Therefore, the best classification is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2010-12-06 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.